Palani Santhosh
SEC insider (Form 3/4/5 filer). CIK 0002013475. Director at Acrivon Therapeutics, Inc. (ACRV) and 1 other issuer. 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 17, 2026. Located in WATERTOWN, MA.
Companies Palani Santhosh has filed insider reports for
- Acrivon Therapeutics, Inc. (ACRV): Director
- Pyxis Oncology, Inc. (PYXS): Director
Palani Santhosh
CIK: 0002013475
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 17, 2026ACRV
Acrivon Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
20.3K shares- - May 18, 2026ACRV
Acrivon Therapeutics, Inc.
AwardDirect9.4K shares- - Mar 24, 2026PYXS
Pyxis Oncology, Inc.
AwardDirectStock Option (Right to Buy)
45.9K shares- - Jun 13, 2025ACRV
Acrivon Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
20.3K shares- - Mar 31, 2025PYXS
Pyxis Oncology, Inc.
AwardDirectStock Option (Right to Buy)
37K shares at avg. $0.98-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 17, 2026 |  ACRV Acrivon Therapeutics, Inc. | Award Stock Option (Right to Buy) | 20,275 | - | - | Direct |
| May 18, 2026 | ACRV Acrivon Therapeutics, Inc. | Award | 9,366 | - | $0 | Direct |
| Mar 24, 2026 |  PYXS Pyxis Oncology, Inc. | Award Stock Option (Right to Buy) | 45,867 | - | - | Direct |
| Jun 13, 2025 | ACRV Acrivon Therapeutics, Inc. | Award Stock Option (Right to Buy) | 20,275 | - | - | Direct |
| Mar 31, 2025 | PYXS Pyxis Oncology, Inc. | Award Stock Option (Right to Buy) | 36,979 | $0.98 | - | Direct |
1-5 of 5 transactions